| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/22/2004 | WO2004007534A1 METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IgE SYNTHESIS UTILIZING A THIOREDOXIN-LIKE 32 kDA PROTEIN |
| 01/22/2004 | WO2004007533A1 Processes for the preparation of fibrinogen |
| 01/22/2004 | WO2004007524A2 Bicyclic oligopeptides |
| 01/22/2004 | WO2004007512A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 01/22/2004 | WO2004007417A1 Enzyme inhibitors |
| 01/22/2004 | WO2004006990A2 Medical device and method for tissue removal and repair |
| 01/22/2004 | WO2004006961A1 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 01/22/2004 | WO2004006958A1 Stable pharmaceutical composition comprising erythropoietin |
| 01/22/2004 | WO2004006954A2 Transdermal botulinum toxin compositions |
| 01/22/2004 | WO2004006950A2 Use of cd152 for treating autoimmune diseases and inflammations |
| 01/22/2004 | WO2004006949A1 Methods and compositions for regulation of mammalian hair growth |
| 01/22/2004 | WO2004006948A1 Stable pharmaceutical composition comprising erythropoietin |
| 01/22/2004 | WO2004006947A1 A method for inhibiting vascular permeability and tissue edema |
| 01/22/2004 | WO2004006941A1 Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders |
| 01/22/2004 | WO2004006939A1 Blocking inflammation by inhibiting st3-gal-vi activity |
| 01/22/2004 | WO2004006920A1 Topical treatment of skin diseases |
| 01/22/2004 | WO2004006915A1 Angiotensin non-at1 receptor stimulating agents for brain ischemia protection and for acute stroke treatment |
| 01/22/2004 | WO2004006908A1 Remedies for pigmentation |
| 01/22/2004 | WO2004006907A1 Modified amino acid for the inhibition of platelet aggregation |
| 01/22/2004 | WO2004006898A2 Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease |
| 01/22/2004 | WO2004006864A2 Methods and compositions for the enhancement of wound healing |
| 01/22/2004 | WO2004006862A2 A method for the modulation of angiogenesis |
| 01/22/2004 | WO2004006856A2 Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression |
| 01/22/2004 | WO2004006853A2 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | WO2004006848A2 Combination therapies with ftc for the treatment of hepatitis b virus infection |
| 01/22/2004 | WO2004006843A2 Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
| 01/22/2004 | WO2004006839A2 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
| 01/22/2004 | WO2004006830A2 Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
| 01/22/2004 | WO2004006756A2 THERAPIES FOR RENAL FAILURE USING INTERFERON-β |
| 01/22/2004 | WO2003097665A3 Mid 241 receptor, a novel g-protein coupled receptor |
| 01/22/2004 | WO2003097107A3 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 01/22/2004 | WO2003094858A3 Ctp-extended erythropoietin |
| 01/22/2004 | WO2003090778A3 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/22/2004 | WO2003089457A3 Peptide inhibitors of protein kinase c ϝ for pain management |
| 01/22/2004 | WO2003087369A3 Ribozyme capable of specifically cleaving mmp-13 |
| 01/22/2004 | WO2003080028A3 Method and apparatus for producing dry particles |
| 01/22/2004 | WO2003076391A3 Urokinase inhibitors, production and use thereof |
| 01/22/2004 | WO2003075946A3 Treatment of type i diabetes mellitus using growth hormone antagonist |
| 01/22/2004 | WO2003072800A3 Haemophilus adherence and penetration proteins |
| 01/22/2004 | WO2003072031A3 Treatment of disease by inducing cell apoptosis |
| 01/22/2004 | WO2003070759A3 Method of modulating e-cadherin mediated cell adhesion |
| 01/22/2004 | WO2003068966A3 REGULATION OF HUMAN Ca2+-PERMEABLE NONSELECTIVE CATION CHANNEL |
| 01/22/2004 | WO2003066087A3 Kinases involved in the regulation of energy homeostasis |
| 01/22/2004 | WO2003066086A3 Proteins involved in the regulation of energy homeostatis |
| 01/22/2004 | WO2003066002A3 IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION |
| 01/22/2004 | WO2003064452A3 Method for the preparation of highly branched polypeptides |
| 01/22/2004 | WO2003060521A3 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 01/22/2004 | WO2003059286A3 Methods and compositions for oxygen transport comprising modified hemoglobin in plasma |
| 01/22/2004 | WO2003055462A3 Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof |
| 01/22/2004 | WO2003054001A3 Method for preparing echinocandin derivatives and their compositions |
| 01/22/2004 | WO2003049693A3 Method and composition for inducing weight loss |
| 01/22/2004 | WO2003048303A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/22/2004 | WO2003048205A3 Novel proteins with il-6 inhibiting activity |
| 01/22/2004 | WO2003045322A3 Method for treating and preventing pancreatitis |
| 01/22/2004 | WO2003045316A3 Polynucleotide therapy |
| 01/22/2004 | WO2003044040A3 Alpha-fetoprotein peptides and uses thereof |
| 01/22/2004 | WO2003027251A3 Novel molecules of the pyrin domain protein family and uses thereof |
| 01/22/2004 | WO2003025121A3 Igf-binding protein-derived peptide or small molecule |
| 01/22/2004 | WO2003024996A3 Antibacterial macrocycles |
| 01/22/2004 | WO2003008595A3 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 01/22/2004 | WO2003001883A3 Gaba b1a receptor disruptions, compositions and methods relating thereto |
| 01/22/2004 | WO2002099120A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 01/22/2004 | WO2002098917A3 Human proteins and nucleic acids encoding same |
| 01/22/2004 | WO2002092622A8 Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors |
| 01/22/2004 | WO2002078643A3 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 01/22/2004 | WO2002076389A3 Compositions and methods to prevent metastasis from primary malignancies |
| 01/22/2004 | WO2002069886A3 Modified proteins, designer toxins, and methods of making thereof |
| 01/22/2004 | WO2002065986A3 Transporters comprising spaced arginine moieties |
| 01/22/2004 | WO2002059143A3 Therapeutic peptides for demyelinating conditions |
| 01/22/2004 | US20040016010 Transgenic non-human mammal whose genome includes disruption of an IL-21 receptor gene such that mammal lacks or has reduced levels of functional IL-21 receptor polypeptide; use in evaluating role of IL-21 in modulating immune responses |
| 01/22/2004 | US20040016006 Chromosome 3p21.3 genes are tumor suppressors |
| 01/22/2004 | US20040014954 Comprises nucleotide sequences coding secreted polypeptides for diagnosing, preventing and treating autoimmune, cancer and transplant disorders; wound healing agents |
| 01/22/2004 | US20040014948 Single-chain antagonist polypeptides |
| 01/22/2004 | US20040014947 Comprises learning enhancement polypeptide for diagnosis, treatment and prevention of nervous system and neural degenerative diseases |
| 01/22/2004 | US20040014942 Transformation cells by introduction of a false-sense mutation at a target codon of a gene coding for a protein necessary for the growth of the cells, such protein synthesized from the gene thus mutated is non functional |
| 01/22/2004 | US20040014940 Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| 01/22/2004 | US20040014814 A method of altering the senescence of cells comprising applying to said cells an effective amount of a composition wherein said composition includes N-acetyl-carnosine as an active ingredient. |
| 01/22/2004 | US20040014778 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 01/22/2004 | US20040014751 Antidiabetic agents |
| 01/22/2004 | US20040014739 Low dosage; anxiolytic agents, psychological disorders, cognition activators |
| 01/22/2004 | US20040014722 Viricides |
| 01/22/2004 | US20040014720 Hypotensive agents |
| 01/22/2004 | US20040014709 Genetic engineered adenoviral vector coding interferon gene; therapy against bladder cancer |
| 01/22/2004 | US20040014705 Supplying polypeptides; coupling with controller; therapy for autoimmune disease |
| 01/22/2004 | US20040014702 Mammalian prostaglandin H synthase-2 |
| 01/22/2004 | US20040014700 Novel oligonucleotides and use of oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments, as depigmentation agents |
| 01/22/2004 | US20040014699 Antisense modulation of PTPRM expression |
| 01/22/2004 | US20040014678 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway |
| 01/22/2004 | US20040014677 Antiinflammatory agents; antihistamines; brain disorders; Alzheimer's disease; inflammatory bowel disorders; antiarthritic agents |
| 01/22/2004 | US20040014676 SRC kinase inhibitors useful for treating osteoporosis |
| 01/22/2004 | US20040014675 Anticancer products for treating cystic fibrosis |
| 01/22/2004 | US20040014674 Gpe analogs |
| 01/22/2004 | US20040014673 Pharmaceutical composition comprising an analgesic peptide |
| 01/22/2004 | US20040014671 Cardiovascular disorders |
| 01/22/2004 | US20040014670 Inhibitors of angiotensin converting enzyme |
| 01/22/2004 | US20040014668 Human NK3-related prostate specific gene 1 |
| 01/22/2004 | US20040014667 Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF); VEGF minitraps useful for treating VEGF-associated conditions and diseases, designed for local administration to specific organs, tissues |
| 01/22/2004 | US20040014665 Genetic engineering; wound healing agents; antidiabetic agents; stimulant gene expression |
| 01/22/2004 | US20040014664 Analyzing tumors; bone disorders; antidiabetic agents; platelet derived endothelial growth factor |
| 01/22/2004 | US20040014663 Botulinum toxin treatment for cervical dystonia |